Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Acute Undifferentiated Leukemia (AUL); Myelodysplastic Syndrome; Chronic Myeloid Leukemia; Non-Hodgkin Lymphoma

Interventions: Biological: Exercise Mobilized Prophylactic DLI; Biological: Standard Prophylactic DLI; Biological: Exercise Mobilized Therapeutic DLI; Biological: Standard Therapeutic DLI

Sponsors: University of Arizona

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 29, 2025Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments